As a senior reporter, Kyle LaHucik covers the financial underpinnings of drug development and breaks news on biotech financing rounds, M&A, IPO planning and other deals pushing the industry forward. A graduate of the University of Missouri School of Journalism, Kyle joined Endpoints News in March 2022 after reporting for Fierce Biotech, Mergermarket, Bloomberg, the Columbia Missourian and other publications. Outside of work, catch him on the Chicago lakefront path, where he coaches a local high school cross country and track team, trains for marathons and bikes for fun.
Sign up for free to read a limited number of articles each month.About You
Pick what newsletters get delivered to your inbox each week.
Want unlimited access? Sign up for a premium subscription plan.
Join over 187,800 biopharma colleagues who rely on Endpoints News every business day for the latest developments in drug discovery, development, and commercialization.